

Course Detail

MMWR Weekly – February 11, 2011

Course Number: SS1747-021111

CE Origination Date: February 11, 2011

CE Expiration Date: March 28, 2011

Content Experts/Prepares

Discordant Results from Reverse Sequence Syphilis Screening – Five Laboratories, United States, 2006-2010

R C Ballard, PhD, Div of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC

G Bolan, MD, California Dept. of Public Health

S Blank, MD, New York City Dept. of Health and Mental Hygiene

Joan Chow, DrPH, MPH, California Dept. of Public Health

D L Cox, PhD, Div of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC

Karen W Hoover, MD, MPH, Div of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC

I Park, MD, California Dept. of Public Health

P Pathela, DrPH, New York City Dept. of Health and Mental Hygiene

J D Radolf, MD, University of Connecticut Health Center

J A Schillinger, MD, New York City Dept. of Health and Mental Hygiene

Suzanne N. Zanto, MPH, Montana Department of Public Health and Human Services, Laboratory Services Bureau

K A Workowski, MD, Div of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC

Decrease in Smoking Prevalence – Minnesota, 1999-2010

Raymond Boyle, PhD, MPH, ClearWay Minnesota

Joanne D'Silva, MPH, ClearWay Minnesota

Ann M. Kinney, PhD, Minnesota Department of Health

Jeong Lyu Lee, PhD, ClearWay Minnesota

Peter A. Rode, MA, Minnesota Department of Health

Ann St. Claire, MPH, ClearWay Minnesota

Megan Whittet, MPH, ClearWay Minnesota

Recommended Immunization Schedules for Persons Aged 0 through 18 Years – United States, 2011

William L. Atkinson, MD, National Center for Immunization and Respiratory Diseases, CDC

Disclosure

CDC, our planners, and our content experts wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters.

Presentations will not include any discussion of the unlabeled use of a product or a product under investigational use with the exception of Dawn Smith's discussion of antiretroviral agents. She will be discussing guidance on the use of antiretroviral agents for the prevention of HIV infection among MSM. Medications have a labeled indication for the treatment of HIV infection but off-label use is permitted. Guidance is based on the results of a large clinical trial showing substantial efficacy for prevention. The pharmaceutical company is in discussions with FDA to apply for a prevention labeling indication. FDA has cleared the content of this interim guidance for off-label use. Dr. Paul Weidle has a discussion on pre-exposure prophylaxis. He will discuss the use of pre-exposure prophylaxis is not a FDA labeled indication for tenofovir/emtricitabine (Truvanda). Dr. Tejpatap Tiwari has a discussion on diphtheria antitoxin. He will be discussing FDA- licensed diphtheria antitoxin (DAT) product being unavailable for use in the USA since 1997. However, DAT is currently available for use under a FDA-approved Investigational New Drug Protocol which is managed by CDC. Physicians/health care providers can obtain DAT from CDC upon request for treatment of suspected diphtheria cases.

No commercial support.

Mechanism(s) to Resolve Real and Perceived Conflicts of Interest: Planner(s) reviewed content and it was cleared before publication.